G2019S Variation in LRRK2: An Ideal Model for the Study of Parkinson’s Disease?

, , , , , , , &
Frontiers in Human Neuroscience 13 (2019)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.3389/fnhum.2019.00306

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,202

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau.Jean-Marc Taymans & Mark R. Cookson - 2010 - Bioessays 32 (3):227-235.
Structures in neuropharmacology. den Bosch & M. P. - 2005 - Poznan Studies in the Philosophy of the Sciences and the Humanities 84 (1):343-359.
Structures in Neuropharmacology.Alexander P. M. van den Bosch - 2005 - Poznan Studies in the Philosophy of the Sciences and the Humanities 84 (1):343-359.
A Shaky Walk Downhill : A Philosopher Moves into Parkinson's World.David Kolb - manuscript
Regulatory Misconception Muddies the Ethical Waters: Challenges to a Qualitative Study.Kimberly M. Yee & Paul J. Ford - 2012 - Journal of Clinical Ethics 23 (3):217-220.
The factor structure of the SF‐36 in Parkinson's disease.Pauline Banks & Colin R. Martin - 2009 - Journal of Evaluation in Clinical Practice 15 (3):460-463.
Ideal Model: Social Cultural Determinants and Phunctions.O. G. Glukhova - 2012 - Anthropological Measurements of Philosophical Research 1:68-72.
The biochemical bases of the placebo effect.Raúl de la Fuente-Fernández & A. Jon Stoessl - 2004 - Science and Engineering Ethics 10 (1):143-150.
Clinical and neuropsychological correlates of impaired awareness of deficits in alzheimer disease and Parkinson disease: A comparative study.Benjamin Seltzer, Jennifer J. Vasterling, Charles W. Mathias & Angela Brennan - 2001 - Neuropsychiatry, Neuropsychology, and Behavioral Neurology 14 (2):122-129.
The biochemical bases of the placebo effect.Dr Raúl de la Fuente-Fernández & A. Jon Stoessl - 2004 - Science and Engineering Ethics 10 (1):143-150.
Brain Atrophy and Reorganization of Structural Network in Parkinson's Disease With Hemiparkinsonism.Xiaojun Xu, Xiaojun Guan, Tao Guo, Qiaoling Zeng, Rong Ye, Jiaqiu Wang, Jianguo Zhong, Min Xuan, Quanquan Gu, Peiyu Huang, Jiali Pu, Baorong Zhang & Minming Zhang - 2018 - Frontiers in Human Neuroscience 12.
Potential Subjects’ Responses to an Ethics Questionnaire in a Phase I Study of Deep Brain Stimulation in Early Parkinson’s Disease.Stuart G. Finder, Mark J. Bliton, Chandler E. Gill, Thomas L. Davis, Peter E. Konrad & P. D. Charles - 2012 - Journal of Clinical Ethics 23 (3):207-216.
Physical models and biological contexts.Margaret Morrison - 1997 - Philosophy of Science 64 (4):324.
Being a Parkinson’s patient: Immobile and unpredictably whimsical Literature and existential analysis. [REVIEW]Harry Van Der Bruggen & Guy Widdershoven - 2004 - Medicine, Health Care and Philosophy 7 (3):289-301.
Scientific evaluation of community‐based Parkinson's disease nurse specialists on patient outcomes and health care costs.Brian Hurwitz, Brian Jarman, Adrian Cook & Madhavi Bajekal - 2005 - Journal of Evaluation in Clinical Practice 11 (2):97-110.

Analytics

Added to PP
2019-09-06

Downloads
16 (#851,323)

6 months
3 (#880,460)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references